Skip to content
DataLookout
Menu

NCT02530034

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 36 versions: 22 with changes below, 14 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: FDA Clinical Hold
    • Final enrollment: 15 participants (planned 72)
    • Primary completion date changed from estimate of Jan 1, 2027 to Oct 15, 2026
  2. Notable Eligibility criteria expanded, about 7 words
    • Interventions: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other) to Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other)
    • Secondary endpoints: details revised at 1 of 4 entries
  3. Notable Primary and study completion dates: Jan 31, 2026 to Jan 1, 2027v33
  4. Study Identification, Study Status, Conditionsv31
  5. Study Identification, Study Status, Conditionsv30
Show 16 earlier versionsHide 16 earlier versions
  1. Notable Primary and study completion dates: Jan 30, 2024 to Jan 31, 2026v28
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 4 of 4 sites
    v25
  3. Minor Study sites: 3 to 4v24
  4. Minor Study sites: 1 to 3v22
  5. Notable Primary and study completion dates: Jan 31, 2022 to Jan 30, 2024v21
  6. Notable Eligibility criteria expanded, about 20 words
    • Site contact updated
    v17
  7. Notable Eligibility criteria shortened, about 31 words
    • Primary endpoints: 1 to 2
    • Enrollment target: 60 to 72
    • Study description expanded, about 1 word
    v15
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v11
  9. Notable Primary endpoints: 2 to 1v9 Show 10 more changesShow less
    • Eligibility criteria shortened, about 1 word
    • Primary and study completion dates: Jan 2022 to Jan 31, 2022
    • Start date: Jan 2019 to Jan 31, 2019
    • Interventions: Hu8F4 (Drug) to Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other)
    • Secondary endpoints revised (4)
    • Study description shortened, about 722 words
    • Study site revised
    • Collaborator revised
    • Study arms: 4 to 1
    • Study title shortened, about 3 words
  10. Notable Start date: Sep 2018 to Jan 2019
    • Primary completion date: Sep 2021 to Jan 2022
    • Study completion date: Sep 2022 to Jan 2022
    • Site contact updated
    v8
  11. Notable Start date: Jun 2018 to Sep 2018v7 Show 4 more changesShow less
    • Eligibility criteria expanded, about 114 words
    • Primary completion date: Jun 2021 to Sep 2021
    • Study completion date: Jun 2022 to Sep 2022
    • Study description expanded, about 51 words
  12. Notable Start date: Mar 2018 to Jun 2018
    • Primary completion date: Mar 2021 to Jun 2021
    • Study completion date: Mar 2021 to Jun 2022
    v6
  13. Minor Primary and study completion dates: Jan 2021 to Mar 2021
    • Start date: Jan 2018 to Mar 2018
    • Study description revised
    v5
  14. Notable Start date: Nov 2016 to Jan 2018v4 Show 5 more changesShow less
    • Primary endpoints: 1 to 2
    • Primary completion date: Nov 2020 to Jan 2021
    • Study completion date: Jan 2021
    • Secondary endpoints expanded, about 35 words
    • Study arms: 1 to 4
  15. Notable Start date: May 2016 to Nov 2016
    • Primary completion date: May 2020 to Nov 2020
    v3
  16. Minor Primary completion date: Dec 2020 to May 2020
    • Start date: Dec 2016 to May 2016
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Minimum safety data
Timeframe: 4 weeks
Biologically-effective dose
Timeframe: 4 weeks

Secondary (4)

Overall survival
Disease-free survival
Event-free survival
Duration of complete remission

Arms and interventions

Treatment (Hu8F4)Experimental

Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drugs: Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4

Other: Laboratory Biomarker Analysis, Pharmacological Study

Sites

4 sites in 1 country